# Supplemental Material

A Comparison of Real-world Effectiveness of Vortioxetine Along the Treatment Algorithm for Major Depressive Disorder

Table 1. Adverse drug reactions (safety population)

|  | **PREVIDA**  **N=498** | **REVIDA**  **N=138** | **TREVIDA**  **N=253** |
| --- | --- | --- | --- |
| Incidence of adverse drug reactions (ADRs)†, n (%) | 12 (2.4) | 13 (9.4) | 9 (3.6) |
| Number of ADRs | 12 | 20 | 11 |
| Abdominal discomfort |  | 4 |  |
| Nausea | 3 | 3 | 3 |
| Severe irritability | 3 |  |  |
| Headache | 3 | 1 |  |
| Somnolence |  | 2 |  |
| Urticaria |  | 2 |  |
| Hypersensitivity |  | 2 |  |
| Skin itchy |  |  | 2 |
| GI upset |  |  | 2 |
| Dizziness |  | 1 | 2 |
| Rash | 1 | 1 |  |
| Diarrhea |  |  | 1 |
| Suicide attempt |  |  | 1 |
| Vertigo | 1 |  |  |
| Orthostatic hypotension | 1 |  |  |
| Drug ineffective |  | 1 |  |
| Not specified |  | 3 |  |
| ADRs leading to study discontinuation, n (%) | 12 (2.4) | 9 (6.5) | 6 (2.4) |
| †Patients with multiple ADRs in the same category were counted only once in that category.  Percentages are based on the number of patients with non-missing values in each specified category.  Abbreviations: ADR, adverse drug reaction; GI, gastrointestinal; n, number of patients with non-missing values in the specific category. | | | |